Neurological features of Fabry disease: clinical, pathophysiological aspects and therapy. - Wikidata - wikimedia - TriplyDB

Neurological features of Fabry disease: clinical, pathophysiological aspects and therapy.

Neurological features of Fabry disease: clinical, pathophysiological aspects and therapy.

http://www.wikidata.org/entity/Q37994740

about

Genetics of vascular dementia - review from the ICVD working group.[Genetics of ischemic stroke].Autophagy-lysosome pathway associated neuropathology and axonal degeneration in the brains of alpha-galactosidase A-deficient mice.Inherited neuropathies: an update.Sphingolipid lysosomal storage disorders.Fabry Disease: Recognition, Diagnosis, and Treatment of Neurological Features.Case report of concurrent Fabry disease and amyotrophic lateral sclerosis supports a common pathway of pathogenesis.Identification of a Missense Mutation in the α-galactosidase A Gene in a Chinese Family with Fabry Disease.

P2860

Q30235432-9DD880A7-1EBA-4EA9-9A65-0F7DF39AA56C Q34555157-34A33D0D-0A10-429B-B079-8F7702C90AA1 Q37600470-8E122469-71F5-4A00-BA13-17F83E5CC4F5 Q38141876-6411EF7A-B695-41B2-898C-3630FF285FDD Q38217766-86CFC1F0-7240-493B-8997-36884B24F547 Q38844401-1EBD3109-4766-4ECA-B6C7-3D5C21CCB8DA Q42288980-D3245D1B-8272-4D17-8225-4C4C0D499F27 Q55379532-F3817B67-3C57-4AAF-BBB5-6FCCE44A0FCD

P2860

Neurological features of Fabry disease: clinical, pathophysiological aspects and therapy.

http://www.wikidata.org/entity/Q37994740

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Neurological features of Fabry disease: clinical, pathophysiological aspects and therapy.

@en

Neurological features of Fabry disease: clinical, pathophysiological aspects and therapy.

@nl

type

label

Neurological features of Fabry disease: clinical, pathophysiological aspects and therapy.

@en

Neurological features of Fabry disease: clinical, pathophysiological aspects and therapy.

@nl

prefLabel

Neurological features of Fabry disease: clinical, pathophysiological aspects and therapy.

@en

Neurological features of Fabry disease: clinical, pathophysiological aspects and therapy.

@nl

P1433

Q37994740-7D1DBAB2-ADE8-4F7B-948D-7660003BC869

P1476

Q37994740-0FE89174-FC01-460F-AD26-D7CD9A80DEEE

P2093

Q37994740-39E5FBE5-6C40-40AD-AE9C-68228E392501

Q37994740-ABC7D5E5-0F69-4011-871B-A2CEECA277D2

Q37994740-DE10A862-9AA7-43FA-980A-95761538C322

Q37994740-F5C9CDFD-B0DC-4C16-8B3B-63E308272846

P2860

Q37994740-032BD2AA-5B54-4DEF-8D2C-F22E287633C3

Q37994740-034E69D4-76C6-491C-A41D-5D86598229AA

Q37994740-03BE395C-1FDF-4B6A-8D38-A7441DCE0931

Q37994740-0496BE89-A446-44A3-BE57-A7FB626540F8

Q37994740-0586F4B0-1EFE-470C-A415-2CD163050673

Q37994740-08F11C26-5688-4F7B-815A-A8439D178801

Q37994740-094878D9-BDED-46F3-B441-D3940C5AF251

Q37994740-0A1C6E00-A780-43F2-88D8-47148D4FCBE7

Q37994740-0B005178-38AF-4785-8B88-39E4572A6D19

Q37994740-0B0B6E93-F0BA-4C37-ABA8-C0DF2CF28CF4

P304

Q37994740-BCF948F1-83DF-485B-9F9A-CF3323EC2F9D

P31

Q37994740-60726773-958B-4790-A117-6B63E1DC2167

P356

Q37994740-A85A0C92-97A5-4494-A6E7-FFCB64EA0EF0

P407

Q37994740-FA174AEA-930E-4E99-AE75-413469E1369D

P433

Q37994740-B2FEAAB6-5BAE-495A-ACA5-6D212595FB49

P478

Q37994740-30946E5E-1CD5-4CC4-9892-73AB342E37B3

P50

Q37994740-4FFB4240-ABBD-471D-BDC5-7D988CEE548F

Q37994740-B927D6F2-4A83-4C92-B645-468CC1E6E3F6

P577

Q37994740-AAAF6C77-FE4F-4879-9031-4CDE575745DA

P698

Q37994740-23DD2010-7E09-42F1-B73A-AEF2FDB52511

P921

Q37994740-14EA4B6A-5322-4FB4-B5B1-1457FA1E0FE1

P356

J.1600-0404.2012.01661.X

P1433

Acta Neurologica Scandinavica

P1476

Neurological features of Fabry disease: clinical, pathophysiological aspects and therapy

@en

P2093

A Bersano

http://www.w3.org/2001/XMLSchema#string

C Valcarenghi

http://www.w3.org/2001/XMLSchema#string

P Baron

http://www.w3.org/2001/XMLSchema#string

S Lanfranconi

http://www.w3.org/2001/XMLSchema#string

P2860

Treatment of Fabry disease: outcome of a comparative trial with agalsidase alfa or beta at a dose of 0.2 mg/kg

Comparison of the effects of agalsidase alfa and agalsidase beta on cultured human Fabry fibroblasts and Fabry mice

Long-term safety and efficacy of enzyme replacement therapy for Fabry disease

Enzyme replacement reverses abnormal cerebrovascular responses in Fabry disease

A phase 1/2 clinical trial of enzyme replacement in fabry disease: pharmacokinetic, substrate clearance, and safety studies

Alpha-galactosidase A deficiency accelerates atherosclerosis in mice with apolipoprotein E deficiency

Effects of enzyme replacement therapy on pain and health related quality of life in patients with Fabry disease: data from FOS (Fabry Outcome Survey).

Clinical manifestations of Fabry disease in children: data from the Fabry Outcome Survey.

Fabry disease: cardiac manifestations and therapeutic options.

Infusion of alpha-galactosidase A reduces tissue globotriaosylceramide storage in patients with Fabry disease.

P304

77-97

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/J.1600-0404.2012.01661.X

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

126

http://www.w3.org/2001/XMLSchema#string

P50

Giuseppe Micieli

P577

2012-03-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22428782

http://www.w3.org/2001/XMLSchema#string

P921

pathophysiology